{'fraction_non_alphanumeric': 0.020512820512820513, 'fraction_numerical': 0.0, 'mean_word_length': 5.508333333333334, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Are triplet therapies really living up to their hype as the “standard of care” for multiple myeloma and what else is needed?

Treatment of multiple myeloma (MM) has changed dramatically over the last two decades and has led to a significant improvement in outcomes for patients of all ages. Triplet combinations are now widely accepted as standard induction therapies for transplant-eligible patients and are also emerging for relapsed/refractory disease, thus evoking considerable enthusiasm among the myeloma community. However, given the ultra-fast development of new treatment regimens, the treating physician will face new challenges in terms of risk-adapted use of these protocols, optimal sequencing and ultimately management of patients with multiclass refractory disease.